Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Interest Expenses (2016 - 2025)

Plus Therapeutics has reported Interest Expenses over the past 15 years, most recently at $548000.0 for Q1 2025.

  • Quarterly Interest Expenses rose 1511.76% to $548000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $548000.0 through Dec 2025, up 206.15% year-over-year, with the annual reading at $548000.0 for FY2025, 206.15% up from the prior year.
  • Interest Expenses was $548000.0 for Q1 2025 at Plus Therapeutics, up from $57000.0 in the prior quarter.
  • Over five years, Interest Expenses peaked at $548000.0 in Q1 2025 and troughed at $27000.0 in Q2 2024.
  • The 5-year median for Interest Expenses is $111500.0 (2022), against an average of $156687.5.
  • Year-over-year, Interest Expenses tumbled 75.89% in 2024 and then soared 1511.76% in 2025.
  • A 5-year view of Interest Expenses shows it stood at $232000.0 in 2021, then crashed by 52.16% to $111000.0 in 2022, then tumbled by 44.14% to $62000.0 in 2023, then dropped by 8.06% to $57000.0 in 2024, then surged by 861.4% to $548000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Interest Expenses are $548000.0 (Q1 2025), $57000.0 (Q4 2024), and $61000.0 (Q3 2024).